ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0342

Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements

Katherine Nay Yaung1, Joo Guan Yeo2, Hui Nee Annie Law3, Martin Wasser4, Thaschawee Arkachaisri5, Julian Thumboo3, Andrea Low3 and Salvatore Albani4, 1Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore; Duke-NUS Medical School, Singapore, Singapore, 2KK Hospital, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, 3Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 4Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, Singapore, 5KK Women's and Children's Hospital, SingHealth, Singapore, Singapore

Meeting: ACR Convergence 2022

Keywords: immunology, longitudinal studies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease that interferes with the balance between regulation and immunity, resulting in immune system dysfunction. Disease course is unpredictable due to alternating remissions and flares, impeding reliable patient assessments. Thus, mechanistic insights are required for better assessment. Current studies are mainly descriptive, and SLE is best interrogated with a multi-parametric, holistic approach such as mass cytometry (CyTOF).

The objectives of this study are as follows: (1) To characterise immune signatures of SLE patients and in the process: Study the roles of B and T cells in SLE to gain a holistic understanding of the adaptive immune response and (2) To compare immunological profiles of SLE patients with age-matched healthy controls.

Methods: Peripheral blood mononuclear cells (PBMCs) from 26 SLE subjects (41 samples, median age 39.5years) and 27 age-matched subjects were tested with CyTOF. Data was analysed and visualised using our laboratory-designed machine learning tool, the Extended Polydimensional Immunome Characterization (EPIC) platform. Normalization and FlowSOM (Flow cytometry analysis by Self- Organising Maps) clustering were performed with functionally and phenotypically important immune markers. Mann-Whitney U test identified significantly different cluster frequencies.

Results: Multiple significant differences were identified (p < 0.05). An activated CD8+CXCR3+CLA+ T -cell subset (CD8+CD45RA+CD38+CLA+CXCR3+) was enriched in SLE (median: 0.19%,interquartile range: 0.13-0.35% of CD45+ PBMCs) versus healthy (0.08%,0.05-0.09%; p< 0.0001). CXCR3 and cutaneous lymphocyte-associated antigen (CLA) are involved in skin-homing, with CLA function enhanced in inflammatory dermatoses. This suggests the importance of skin involvement in SLE immunopathogenesis even if skin manifestations are absent. Further analysis of CD3+ cells revealed unchanged natural T-regulatory cells (TREGS) in healthy and disease while a few TREG-like populations (FoxP3+CD25-) are significantly increased in disease, suggesting a deranged immunoregulatory response driven by TREGS. Thirdly, an activated CD8+BAFF+ T-cell subset (CD8+CD45RA+iCOS+ BAFF+) (r=0.715, p< 0.0001) is enriched in SLE (0.975%,0.433-1.53%) versus healthy (0.28%,0.1-0.49%; p< 0.0001). B-cell activating factor (BAFF) supports autoreactive B cell survival in autoimmune disease; an anti-BAFF drug (belimumab) is FDA- approved for SLE. Despite increasing use of belimumab, not all patients respond equally, so BAFF inhibition alone may not adequately alter disease activity. Studying these cell subset interactions in further detail to identify pathological pathways may facilitate improvements in current SLE theragnostics.

Conclusion: With a multi-parametric unbiased approach comparing SLE subjects to healthy controls, we identified immune subsets of immunopathogenic importance for further studies.

Supporting image 1

Figure 1: Clinical samples are used for experimentation and subsequent analysis.

Supporting image 2

Figure 2: A graphic representation of the EPIC Immunomics Platform, which provides a healthy dataset and analysis pipeline to identify derangements in disease.

Supporting image 3

Figure 3: There are derangements in multiple subsets in SLE. Notably, many differences between SLE and healthy were observed in the CD3+ compartment (circled in red).


Disclosures: K. Nay Yaung, None; J. Yeo, None; H. Law, None; M. Wasser, None; T. Arkachaisri, None; J. Thumboo, None; A. Low, None; S. Albani, None.

To cite this abstract in AMA style:

Nay Yaung K, Yeo J, Law H, Wasser M, Arkachaisri T, Thumboo J, Low A, Albani S. Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/multi-parametric-interrogation-of-the-systemic-lupus-erythematosus-sle-immunome-reveals-multiple-derangements/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multi-parametric-interrogation-of-the-systemic-lupus-erythematosus-sle-immunome-reveals-multiple-derangements/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology